文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan.

作者信息

Suzuki Kazuhito, Fujimori Yuma, Sakai Chika, Tsuchiya Hiroaki, Koroki Yosuke

机构信息

Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.

Johnson & Johnson, Tokyo 101-0065, Japan.

出版信息

Cancers (Basel). 2025 Apr 22;17(9):1389. doi: 10.3390/cancers17091389.

DOI:10.3390/cancers17091389
PMID:40361315
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12070933/
Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal proliferation of plasma cells that leads to bone disease, including lytic lesions and osteoporosis [...].

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/608c909e2d7f/cancers-17-01389-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/4b998aa08ff3/cancers-17-01389-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/c606c8e02fa6/cancers-17-01389-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/6b02a5b1b8db/cancers-17-01389-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/ae34e82e8b68/cancers-17-01389-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/0bedee074834/cancers-17-01389-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/e357fc006b6f/cancers-17-01389-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/608c909e2d7f/cancers-17-01389-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/4b998aa08ff3/cancers-17-01389-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/c606c8e02fa6/cancers-17-01389-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/6b02a5b1b8db/cancers-17-01389-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/ae34e82e8b68/cancers-17-01389-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/0bedee074834/cancers-17-01389-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/e357fc006b6f/cancers-17-01389-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf3b/12070933/608c909e2d7f/cancers-17-01389-g003.jpg

相似文献

[1]
Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan.

Cancers (Basel). 2025-4-22

[2]
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

Lancet Oncol. 2021-11

[3]
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.

J Manag Care Spec Pharm. 2021-12

[4]
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Nat Med. 2025-4

[5]
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.

Oncologist. 2020-12

[6]
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.

JAMA Oncol. 2021-6-1

[7]
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.

Int J Hematol. 2020-1-30

[8]
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med. 2019-5-30

[9]
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.

Cochrane Database Syst Rev. 2024-5-2

[10]
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Cancer Med. 2024-11

本文引用的文献

[1]
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.

Leukemia. 2025-4

[2]
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.

Eur J Haematol. 2025-5

[3]
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.

PLoS One. 2025-1-23

[4]
Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study.

Clin Hematol Int. 2024-10-11

[5]
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).

Int J Hematol. 2024-6

[6]
Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.

Life (Basel). 2024-3-15

[7]
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database.

PLoS One. 2023

[8]
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.

Oncologist. 2023-5-8

[9]
Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China.

Front Pharmacol. 2023-1-12

[10]
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

J Clin Oncol. 2023-3-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索